Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights
FDA PDUFA goal date of August 15, 2025, for TNX‑102 SL for fibromyalgia: if approved by FDA, TNX‑102 SL would be the first new drug for fibromyalgia in more than 16 years
How will the earnings results and operational highlights reported for Q2 2025 influence the broader market narrative around Tonix’s growth trajectory?
What historical price reaction has Tonix experienced around similar FDA decision milestones, and can that inform expected volatility?
Are there any contingent milestones or partnership agreements tied to the approval of TNX‑102 SL that could further move the stock?
26 days ago